Bicycle Therapeutics Target Price

Cambridge england boston business wire sep.

Bicycle therapeutics target price. The community is currently still undecided about bicycle therapeutics ltd. Their average twelve month price target is 21 30 predicting that the stock has a possible upside of 18 53. Bicycle conjugates our bicycle conjugates including both toxin conjugates and targeted innate immune activators are designed to rapidly deliver drugs systemically. Sep 03 2020 bicycle therapeutics to participate in upcoming virtual investor conferences.

5 wall street analysts have issued ratings and price targets for bicycle therapeutics in the last 12 months. A loss of 2 170 shows a downward development for bicycle therapeutics ltd. The high price target for bcyc is 27 00 and the low price target for bcyc is 14 00. Its lead product candidate is bt1718 a bicycle toxin conjugate btc which is in phase i iia.

25 2020 bicycle therapeutics plc nasdaq. With 1 buy predictions and 1 sell predictions. Cambridge england boston business wire feb. Bicycle therapeutics company profile.

Bicycle s internal programs are focused on oncology indications with high unmet medical need. Bicycle therapeutics has an average rating of buy and an average price target of 20 75. Bicycle in collaboration with ddf is developing bicycles to modulate the activity of proteins implicated in the progression of dementia. 3 2020 bicycle therapeutics.

With a target price of 18 00 there is a positive potential of 33 333 for bicycle therapeutics ltd. Canaccord genuity reaffirmed a buy rating and issued a 23 50 price target on shares of bicycle therapeutics in a research note on tuesday may 12th. There are currently 5 buy ratings for the. Bicycle will receive a 30 million upfront payment.

Its lead product candidate bt1718 is a bicycle toxin conjugate that is designed to target tumors that express mt1 mmp. Compared to the current price of 13 50. The company has developed bicycles that show successful binding to a target of interest representing the first part of the first milestone of the collaboration. Bicycle has a novel and proprietary phage display screening platform that we use to identify bicycles in an efficient manner.

Bcyc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic. Bt1718 is being investigated for safety tolerability. Upfront payment and potential discovery development regulatory and commercial milestones could total up to 1 7 billion. Oppenheimer reissued a buy rating and set a 27 00 target price on shares of bicycle therapeutics in a research note on tuesday.

Bidaskclub raised shares of bicycle therapeutics from a buy rating to a strong buy rating in a research note on friday july 17th.